Clinical trials · Philadelphia, PA
Metastatic Solid Tumor clinical trials in Philadelphia
We’re tracking 89 recruiting metastatic solid tumor studies with a site in or near Philadelphia — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Philadelphia
- NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05907980RecruitingPhase 1
ROSE12 alone and with other drugs for advanced solid tumors
This trial tests a new drug called ROSE12, given alone or with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapies. The study aims to see if ROSE12 is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06352359RecruitingPhase 1
Study of ONC 841 for advanced solid tumors
This phase 1 study tests an experimental drug called ONC 841 for people with advanced solid tumors that have not responded to other treatments. The trial aims to find a safe dose and see if the drug can shrink tumors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05384626RecruitingPhase 1/Phase 2
Study of an ALK-targeted drug for ALK-positive lung cancer
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Philadelphia, PennsylvaniaAges 12 years+ - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for cancers with a KRAS G12D mutation
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05503797RecruitingPhase 2
Study of FORE8394 for cancers with BRAF changes
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
Philadelphia, PennsylvaniaAges 8 years+ - NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Camden, New JerseyAges 18 years+ - NCT04300556RecruitingPhase 1/Phase 2
Testing an antibody-drug for advanced certain cancers
This early-phase trial tests a treatment called MORAb-202, an antibody “delivery” drug, to see if it’s safe and can help shrink or control certain advanced cancers. It may help people whose tumors match the study’s specific cancer types and prior treatment history.
Camden, New JerseyAges 18 years+ - NCT02474160Recruiting
Banking cancer tissue and blood for future research
This study collects and stores leftover or newly taken samples of tissue and blood from people with cancer. The goal is to build a research library that can help investigators study cancer and develop better tests or treatments.
Wilmington, DelawareAges 2 months+ - NCT05270213RecruitingPhase 1
RBS2418 for advanced cancers after standard treatments
This early-phase study tests RBS2418 in people with advanced, metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or help control disease, and to learn what doses are safest.
Newark, DelawareAges 18 years+ - NCT05584670RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
Newark, DelawareAges 18 years+ - NCT04617522RecruitingPhase 1
Sacituzumab govitecan for advanced cancers with moderate liver issues
This Phase 1 study tests how safe and tolerable sacituzumab govitecan is for people with advanced or metastatic solid tumors who also have moderate liver impairment. It aims to find the right dosing so the treatment can be used more safely in this liver-risk group.
Newark, DelawareAges 18 years+ - NCT07261631RecruitingPhase 1
A study of a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
Princeton, New JerseyAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Bethlehem, PennsylvaniaAges 18 years+ - NCT04165772RecruitingPhase 2
Dostarlimab for locally advanced mismatch-repair deficient solid tumors
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Allentown, PennsylvaniaAges 18 years+
Hear when a new Metastatic Solid Tumor trial opens near Philadelphia, PA
We’ll email you when one opens near Philadelphia, PA — at most once a week, no account needed, unsubscribe anytime.
Metastatic Solid Tumor trials in other cities
Where these studies are running near Philadelphia
Institutions with a site for the recruiting metastatic solid tumor studies listed above.
- Christiana Care Health System-Christiana Hospital · 3 studies
- MD Anderson Cancer Center at Cooper · 2 studies
- University of Pennsylvania/Abramson Cancer Center · 2 studies
- Alliance Cancer Specialists, PC
- Christiana Care Health System - Newark- Site Number : 8400011
- Christiana Care Health System-Wilmington Hospital
- Delaware Clinical and Laboratory Physicians PA
- Fox Chase Cancer Center
What taking part in a metastatic solid tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic solid tumor studies in Pennsylvania.
Common questions
- Are there metastatic solid tumor clinical trials near Philadelphia?
- Yes. We're currently tracking 89 recruiting metastatic solid tumor studies with a site near Philadelphia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic solid tumor study near Philadelphia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Philadelphia to take part?
- Not necessarily. These studies have a site near Philadelphia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic solid tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic solid tumor studies open near Philadelphia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.